Themis Medicare Appoints Nagraj Mogaveera as Interim Company Secretary
Themis Medicare Limited's Board approved financial results for Q3 FY26. Mr. Pradeep M. Chandan resigned as Company Secretary, and Mr. Nagraj Mogaveera was appointed as Interim Company Secretary. The company also approved issuing convertible warrants to promoters and an inter-se transfer of shares in Gujarat Themis Biosyn Limited.
The appointment of an interim Company Secretary is a standard operational update. The approval for convertible warrants and the inter-se transfer of shares in a subsidiary are significant corporate actions that could impact the company's capital structure and internal management, warranting a medium impact.
The announcement includes routine financial reporting and management changes, which are neutral events. While the issuance of warrants could be seen positively, it is subject to approvals and is a forward-looking statement.
Themis Medicare Limited announced the outcome of its Board Meeting held on February 13, 2026. The Board considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2025, along with the Limited Review Report.
The Board also noted the resignation of Mr. Pradeep M. Chandan from the position of Company Secretary, Compliance Officer & Key Managerial Personnel (KMP), effective February 13, 2026, due to other professional commitments.
Subsequently, the Board approved the appointment of Mr. Nagraj Mogaveera as Interim Company Secretary, Compliance Officer & KMP, effective February 14, 2026. Mr. Mogaveera is a qualified Company Secretary with 8 years of experience in company secretarial and corporate governance matters.
Furthermore, the Board approved a proposal for the issuance of convertible equity warrants to Promoter/Promoter Groups via preferential allotment, subject to regulatory and shareholder approvals. A Preferential Issue Committee has been formed to finalize the terms. The issue is proposed for up to 4.99% of the total shareholding, equivalent to 45,95,795 equity shares.
Additionally, the Board approved an inter-se transfer of up to 3% of the paid-up equity share capital of Gujarat Themis Biosyn Limited (GTBL) held by Themis Medicare Limited, to another Promoter/Promoter Group at the prevailing market price. This transaction is an internal transfer within the Promoter/Promoter Group and will not alter the control or overall shareholding.
What to do with a filing like this
Themis Medicare Limited filed this with the NSE as a statutory disclosure, categorised under board meeting. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Themis Medicare Limited. Read the original for the full detail.